E Fund Management’s Catalyst Pharmaceutical CPRX Stock Holding History

E Fund Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Sell	11,669 -3,508	-23%	-$104K	0.01%	348
2026 Q1	$376K	Buy	+15,177	New	+$362K	0.01%	342
2025 Q2	$231K	Buy	10,656 +871	+9%	+$20.6K	0.01%	346
2025 Q1	$237K	Buy	+9,785	New	+$220K	0.01%	346
2024 Q3	–	Sell	-11,266	Closed	-$175K	–	360
2024 Q2	$175K	Sell	11,266 -11,737	-51%	-$183K	0.01%	299
2024 Q1	$367K	Buy	23,003 +4,090	+22%	+$61.6K	0.02%	246
2023 Q4	$318K	Sell	18,913 -7,307	-28%	-$99.9K	0.02%	222
2023 Q3	$307K	Sell	26,220 -12,218	-32%	-$163K	0.02%	203
2023 Q2	$517K	Buy	38,438 +12,059	+46%	+$174K	0.04%	111
2023 Q1	$437K	Buy	26,379 +565	+2%	+$9.32K	0.03%	141
2022 Q4	$480K	Sell	25,814 -2,011	-7%	-$31K	0.04%	134
2022 Q3	$357K	Buy	27,825 +6,490	+30%	+$76.9K	0.03%	205
2022 Q2	$150K	Buy	21,335 +9,721	+84%	+$71.3K	0.01%	310
2022 Q1	$96K	Buy	+11,614	New	+$82.1K	﹤0.01%	316
2021 Q4	–	Sell	-10,838	Closed	-$57K	–	303
2021 Q3	$57K	Buy	+10,838	New	+$59.3K	﹤0.01%	267
2021 Q1	$84K	Buy	+18,138	New	+$72.1K	0.01%	246

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

E Fund Management's CPRX Position: Q2 2026 in Review

E Fund Management reduced its Catalyst Pharmaceutical (CPRX) stake by 23% in Q2 2026, selling an estimated $104K and leaving 11,669 shares worth $367K. The position accounts for 0.01% of the portfolio, ranked #348.

E Fund Management first reported a position in CPRX in Q1 2021 and has held it in 16 quarters since. The position peaked at $517K in Q2 2023. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

E Fund Management held 11,669 shares of Catalyst Pharmaceutical worth $367K as of Q2 2026.
E Fund Management sold 3,508 Catalyst Pharmaceutical shares in Q2 2026, an estimated $104K.
Catalyst Pharmaceutical made up 0.01% of E Fund Management's portfolio in Q2 2026, its #348 holding.
E Fund Management first reported a position in Catalyst Pharmaceutical in Q1 2021 and has held it in 16 quarters since.
E Fund Management's Catalyst Pharmaceutical position peaked at $517K in Q2 2023.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.